14 October 2022>: Clinical Research
Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer
Zin W. Myint 12ABCDEFG* , Jill M. Kolesar 23CDE , Joseph Robert McCorkle 2CDE , Jianrong Wu 4C , Carleton S. Ellis 23CDE , Danielle E. Otto 23CDE , Peng Wang 12ACDEDOI: 10.12659/MSM.938091
Med Sci Monit 2022; 28:e938091
Table 6 Logistic regression between 3-month abiraterone trough level and 3-month prostate-specific antigen ≤1 ng/mL and 7-month abiraterone trough level and 7-month prostate-specific antigen ≤0.2 ng/mL.
PSA | N | mean (tABI)a | P value |
---|---|---|---|
3 months | |||
PSA ≤1 | 6 | 14.59 | 0.25 |
PSA >1 | 3 | 5.51 | |
7 months | |||
PSA ≤0.2 | 4 | 15.90 | 0.56 |
PSA >0.2 | 11.5 | ||
a tABI, trough abiraterone; PSA – prostate-specific antigen. |